Related Experiment Video

Updated: Jul 26, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

DMU-212 against EGFR-mutant non-small cell lung cancer via AMPK/PI3K/Erk signaling pathway

Xiao-Ping Zhao1, Xiao-Li Zheng1, Min Huang1

  • 1Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Dr. Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau, SAR, China.

Heliyon
|June 12, 2023
PubMed

Insights

DMU-212, a resveratrol analog, effectively inhibits non-small cell lung cancer (NSCLC) growth by targeting AMPK and EGFR pathways, offering a potential new treatment for EGFR-mutant NSCLC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) management remains challenging due to low cure and survival rates.
  • Epidermal growth factor receptor (EGFR) is a key target in NSCLC treatment.
  • The anti-cancer effects of DMU-212, a resveratrol analog, on lung cancer are largely unknown.

Purpose of the Study:

  • To investigate the effects of DMU-212 on EGFR-mutant NSCLC cells.
  • To elucidate the underlying molecular mechanisms of DMU-212's action in NSCLC.

Main Methods:

  • Assessed DMU-212 cytotoxicity on EGFR-mutant NSCLC cell lines and normal lung cells.
  • Analyzed DMU-212's impact on cell cycle progression (G2/M phase arrest) and related proteins (p21, cyclin B1).
  • Investigated DMU-212's effects on AMPK activation, EGFR expression, and downstream signaling pathways (PI3K/Akt/ERK).

Main Results:

  • DMU-212 exhibited significantly higher cytotoxicity against EGFR-mutant NSCLC cells compared to normal cells.
  • DMU-212 induced G2/M phase arrest in NSCLC cells by regulating p21 and cyclin B1 expression.
  • DMU-212 activated AMPK and downregulated EGFR expression and PI3K/Akt/ERK phosphorylation.

Conclusions:

  • DMU-212 demonstrates potent anti-cancer activity against EGFR-mutant NSCLC.
  • The anti-proliferative effects of DMU-212 are mediated through the AMPK and EGFR signaling pathways.
  • DMU-212 represents a promising therapeutic candidate for NSCLC treatment.
Keywords:
DMU-212EGFR mutationEGFR-AMPK pathwayLung cancerNSCLC

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K